{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:35:26Z","timestamp":1792614926128,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40120-024-00603-y","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T14:02:26Z","timestamp":1712584946000},"page":"519-533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Narrative Review on the Use of Cladribine Tablets as Exit Therapy for Stable Elderly Patients with Multiple Sclerosis"],"prefix":"10.1007","volume":"13","author":[{"given":"Jerome","family":"de Seze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Dive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Ayrignac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Castelnovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Payet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amel","family":"Rayah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vermersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"603_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231199820","author":"SLS Jacober","year":"2023","unstructured":"Jacober SLS, Disanto G, Sacco R, et al. Interplay between age and disease-modifying treatments in influencing infection risk in multiple sclerosis. Mult Scler. 2023. https:\/\/doi.org\/10.1177\/13524585231199820.","journal-title":"Mult Scler"},{"key":"603_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104245","volume":"68","author":"R Knapp","year":"2022","unstructured":"Knapp R, Hardtstock F, Krieger J, et al. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: a German claims data study. Mult Scler Relat Disord. 2022;68:104245.","journal-title":"Mult Scler Relat Disord"},{"key":"603_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40120-020-00187-3","volume":"9","author":"IA AlSharoqi","year":"2020","unstructured":"AlSharoqi IA, Aljumah M, Bohlega S, et al. Immune reconstitution therapy or continuous immunosuppression for the management of active relapsing-remitting multiple sclerosis patients? A narrative review. Neurol Ther. 2020;9:55\u201366.","journal-title":"Neurol Ther"},{"key":"603_CR4","doi-asserted-by":"publisher","first-page":"175628641983691","DOI":"10.1177\/1756286419836913","volume":"12","author":"PS Sorensen","year":"2019","unstructured":"Sorensen PS, Sellebjerg F. Pulsed immune reconstitution therapy in multiple sclerosis. Ther Adv Neurol Disord. 2019;12:1756286419836913.","journal-title":"Ther Adv Neurol Disord"},{"key":"603_CR5","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1007\/s10238-022-00981-3","volume":"23","author":"P Kazakou","year":"2023","unstructured":"Kazakou P, Tzanetakos D, Vakrakou AG, et al. Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study. Clin Exp Med. 2023;23:2885\u201394.","journal-title":"Clin Exp Med"},{"key":"603_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102492","volume":"19","author":"J Sellner","year":"2020","unstructured":"Sellner J, Rommer PS. Immunological consequences of \u201cimmune reconstitution therapy\u201d in multiple sclerosis: a systematic review. Autoimmun Rev. 2020;19:102492.","journal-title":"Autoimmun Rev"},{"key":"603_CR7","unstructured":"European Medicines Agency. Lemtrada. Measures to minimise risk of serious side effects of multiple sclerosis medicine Lemtrada. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/lemtrada. Accessed Jul 2023."},{"key":"603_CR8","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1007\/s00415-019-09257-5","volume":"266","author":"S Richter","year":"2019","unstructured":"Richter S, Wagner B, Celius EG. Two cases of diabetes mellitus type\u00a01 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease. J Neurol. 2019;266:1270\u20131.","journal-title":"J Neurol"},{"key":"603_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2224556","author":"GD Costa","year":"2023","unstructured":"Costa GD, Comi G. A safety review of current monoclonal antibodies used to treat multiple sclerosis. Expert Opin Drug Saf. 2023. https:\/\/doi.org\/10.1080\/14740338.2023.2224556.","journal-title":"Expert Opin Drug Saf"},{"key":"603_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41409-019-0684-0","volume":"55","author":"B Sharrack","year":"2020","unstructured":"Sharrack B, Saccardi R, Alexander T, et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant. 2020;55:283\u2013306.","journal-title":"Bone Marrow Transplant"},{"key":"603_CR11","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1212\/WNL.0000000000002745","volume":"86","author":"M Buttmann","year":"2016","unstructured":"Buttmann M, Seuffert L, M\u00e4der U, Toyka KV. Malignancies after mitoxantrone for multiple sclerosis: a retrospective cohort study. Neurology. 2016;86:2203\u20137.","journal-title":"Neurology"},{"key":"603_CR12","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1212\/WNL.0b013e3181e0f7e6","volume":"74","author":"E Kingwell","year":"2010","unstructured":"Kingwell E, Koch M, Leung B, et al. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology. 2010;74:1822\u20136.","journal-title":"Neurology"},{"key":"603_CR13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1212\/WNL.0b013e3181cf6ec0","volume":"74","author":"RA Marrie","year":"2010","unstructured":"Marrie RA, Yu N, Blanchard J, Leung S, Elliott L. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology. 2010;74:465\u201371.","journal-title":"Neurology"},{"key":"603_CR14","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1177\/1352458514561904","volume":"21","author":"C Solaro","year":"2015","unstructured":"Solaro C, Ponzio M, Moran E, et al. The changing face of multiple sclerosis: prevalence and incidence in an aging population. Mult Scler. 2015;21:1244\u201350.","journal-title":"Mult Scler"},{"key":"603_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/1352458518815602","volume":"26","author":"S Vukusic","year":"2020","unstructured":"Vukusic S, Casey R, Rollot F, et al. Observatoire Fran\u00e7ais de la Scl\u00e9rose en Plaques (OFSEP): a unique multimodal nationwide MS registry in France. Mult Scler. 2020;26:118\u201322.","journal-title":"Mult Scler"},{"key":"603_CR16","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.2147\/NDT.S143180","volume":"13","author":"E Blozik","year":"2017","unstructured":"Blozik E, Rapold R, Eichler K, Reich O. Epidemiology and costs of multiple sclerosis in Switzerland: an analysis of health-care claims data, 2011\u20132015. Neuropsychiatr Dis Treat. 2017;13:2737\u201345.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"18","key":"603_CR17","first-page":"269","volume":"2019","author":"GBD 2016 Multiple Sclerosis Collaborators","year":"2016","unstructured":"GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990\u20132016: a systematic analysis for the global burden of disease study. Lancet Neurol. 2016;2019(18):269\u201385.","journal-title":"Lancet Neurol"},{"key":"603_CR18","doi-asserted-by":"publisher","first-page":"1073278","DOI":"10.3389\/fpubh.2023.1073278","volume":"11","author":"Z Qian","year":"2023","unstructured":"Qian Z, Li Y, Guan Z, et al. Global, regional, and national burden of multiple sclerosis from 1990 to 2019: findings of global burden of disease study 2019. Front Public Health. 2023;11:1073278.","journal-title":"Front Public Health"},{"key":"603_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1136\/jnnp-2016-315238","volume":"88","author":"HMB Lunde","year":"2017","unstructured":"Lunde HMB, Assmus J, Myhr KM, B\u00f8 L, Grytten N. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry. 2017;88:621\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"603_CR20","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1136\/jnnp-2022-329169","volume":"93","author":"JS Willumsen","year":"2022","unstructured":"Willumsen JS, Grytten N, Aarseth J, Myklebust T\u00c5, Myhr KM, Midgard R. Mortality and cause of death in multiple sclerosis in western Norway\u00a01950\u20132021: a registry-based linkage study. J Neurol Neurosurg Psychiatry. 2022;93(11):1154\u201361.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"17","key":"603_CR21","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1212\/WNL.0b013e3182535cf6","volume":"78","author":"DS Goodin","year":"2012","unstructured":"Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21\u00a0years after the start of the pivotal IFN\u03b2-1b trial. Neurology. 2012;78(17):1315\u201322.","journal-title":"Neurology"},{"key":"603_CR22","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1093\/brain\/awz055","volume":"142","author":"E Kingwell","year":"2019","unstructured":"Kingwell E, Leray E, Zhu F, et al. Multiple sclerosis: effect of beta interferon treatment on survival. Brain. 2019;142:1324\u201333.","journal-title":"Brain"},{"key":"603_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.7224\/1537-2073.2016-067","volume":"19","author":"MH Rabadi","year":"2017","unstructured":"Rabadi MH, Aston CE. Predictors of mortality in veterans with multiple sclerosis in an outpatient clinic setting. Int J MS Care. 2017;19:265\u201373.","journal-title":"Int J MS Care"},{"key":"603_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200005","volume":"9","author":"HS Ng","year":"2022","unstructured":"Ng HS, Zhu F, Kingwell E, et al. Disease-modifying drugs for multiple sclerosis and association with survival. Neurol Neuroimmunol Neuroinflamm. 2022;9: e200005.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"603_CR25","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40261-013-0108-7","volume":"33","author":"CP Tsai","year":"2013","unstructured":"Tsai CP, Lee CT. Impact of disease-modifying therapies on the survival of patients with multiple sclerosis in Taiwan, 1997\u20132008. Clin Drug Investig. 2013;33:647\u201352.","journal-title":"Clin Drug Investig"},{"key":"603_CR26","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1136\/jnnp-2017-315907","volume":"88","author":"N Koch-Henriksen","year":"2017","unstructured":"Koch-Henriksen N, Laursen B, Stenager E, Magyari M. Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study. J Neurol Neurosurg Psychiatry. 2017;88:626\u201331.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"603_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s13670-015-0128-7","volume":"4","author":"CS Riley","year":"2015","unstructured":"Riley CS, Vargas W. Multiple sclerosis in the elderly: considerations in the geriatric population for diagnosis and management. Curr Geriatr Rep. 2015;4:131\u201341.","journal-title":"Curr Geriatr Rep"},{"key":"603_CR28","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1177\/1352458516630396","volume":"22","author":"A Scalfari","year":"2016","unstructured":"Scalfari A, Lederer C, Daumer M, Nicholas R, Ebers GC, Muraro PA. The relationship of age with the clinical phenotype in multiple sclerosis. Mult Scler. 2016;22:1750\u20138.","journal-title":"Mult Scler"},{"key":"603_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11910-020-01046-2","volume":"20","author":"B Zeydan","year":"2020","unstructured":"Zeydan B, Kantarci OH. Impact of age on multiple sclerosis disease activity and progression. Curr Neurol Neurosci Rep. 2020;20:24.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"603_CR30","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","volume":"79","author":"H Tremlett","year":"2008","unstructured":"Tremlett H, Zhao Y, Joseph J, Devonshire V, UBCMS Clinic Neurologists. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry. 2008;79:1368\u201374.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"603_CR31","first-page":"205521731877861","volume":"4","author":"J G\u00e4rtner","year":"2018","unstructured":"G\u00e4rtner J, Chitnis T, Ghezzi A, et al. Relapse rate and MRI activity in young adult patients with multiple sclerosis: a post hoc analysis of phase\u00a03 fingolimod trials. Mult Scler J Exp Transl Clin. 2018;4:2055217318778610.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"603_CR32","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/1352458516634871","volume":"22","author":"SA Sanai","year":"2016","unstructured":"Sanai SA, Saini V, Benedict RHB, et al. Aging and multiple sclerosis. Mult Scler J. 2016;22:717\u201325.","journal-title":"Mult Scler J"},{"key":"603_CR33","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001094","volume":"8","author":"M Eschborn","year":"2021","unstructured":"Eschborn M, Pawlitzki M, Wirth T, et al. Evaluation of age-dependent immune signatures in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021;8: e1094.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"603_CR34","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/brain\/awv395","volume":"139","author":"KS Rawji","year":"2016","unstructured":"Rawji KS, Mishra MK, Michaels NJ, Rivest S, Stys PK, Yong VW. Immunosenescence of microglia and macrophages: impact on the ageing central nervous system. Brain. 2016;139:653\u201361.","journal-title":"Brain"},{"key":"603_CR35","first-page":"41","volume":"41","author":"AAK Balusha","year":"2021","unstructured":"Balusha AAK, Morrow SA. Multiple sclerosis in people over age 55. Pract Neurol. 2021;41:41\u20133.","journal-title":"Pract Neurol"},{"key":"603_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41392-023-01502-8","volume":"8","author":"X Li","year":"2023","unstructured":"Li X, Li C, Zhang W, Wang Y, Qian P, Huang H. Inflammation and aging: signaling pathways and intervention therapies. Signal Transduct Target Ther. 2023;8:239.","journal-title":"Signal Transduct Target Ther"},{"key":"603_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s12016-021-08899-6","volume":"64","author":"T Fulop","year":"2023","unstructured":"Fulop T, Larbi A, Pawelec G, et al. Immunology of aging: the birth of inflammaging. Clin Rev Allergy Immunol. 2023;64:109\u201322.","journal-title":"Clin Rev Allergy Immunol"},{"key":"603_CR38","doi-asserted-by":"publisher","first-page":"1234572","DOI":"10.3389\/fragi.2023.1234572","volume":"4","author":"S Thakolwiboon","year":"2023","unstructured":"Thakolwiboon S, Mills EA, Yang J, et al. Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration. Front Aging. 2023;4:1234572.","journal-title":"Front Aging"},{"key":"603_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.829331","volume":"13","author":"MC Buscarinu","year":"2022","unstructured":"Buscarinu MC, Reni\u00e8 R, Morena E, et al. Late-onset MS: disease course and safety-efficacy of DMTS. Front Neurol. 2022;13: 829331.","journal-title":"Front Neurol"},{"key":"603_CR40","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1212\/WNL.0000000000001718","volume":"85","author":"RA Marrie","year":"2015","unstructured":"Marrie RA, Elliott L, Marriott J, et al. Effect of comorbidity on mortality in multiple sclerosis. Neurology. 2015;85:240\u20137.","journal-title":"Neurology"},{"key":"603_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102815","volume":"50","author":"A Ostolaza","year":"2021","unstructured":"Ostolaza A, Corroza J, Ayuso T. Multiple sclerosis and aging: comorbidity and treatment challenges. Mult Scler Relat Disord. 2021;50: 102815.","journal-title":"Mult Scler Relat Disord"},{"key":"603_CR42","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12883-021-02347-w","volume":"21","author":"F Patti","year":"2021","unstructured":"Patti F, Penaherrera JN, Zieger L, Wicklein EM. Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study. BMC Neurol. 2021;21:324.","journal-title":"BMC Neurol"},{"key":"603_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211120","volume":"14","author":"N Frahm","year":"2019","unstructured":"Frahm N, Hecker M, Zettl UK. Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: a single-center study. PLoS ONE. 2019;14:e0211120.","journal-title":"PLoS ONE"},{"key":"603_CR44","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/pds.4207","volume":"26","author":"C Evans","year":"2017","unstructured":"Evans C, Marrie RA, Zhu F, et al. Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations. Pharmacoepidemiol Drug Saf. 2017;26:702\u201311.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"603_CR45","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.msard.2019.03.024","volume":"31","author":"HL Gullo","year":"2019","unstructured":"Gullo HL, Fleming J, Bennett S, Shum DHK. Cognitive and physical fatigue are associated with distinct problems in daily functioning, role fulfilment, and quality of life in multiple sclerosis. Mult Scler Relat Disord. 2019;31:118\u201323.","journal-title":"Mult Scler Relat Disord"},{"key":"603_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5455\/msm.2022.33.19-24","volume":"34","author":"S Sabanagic-Hajric","year":"2022","unstructured":"Sabanagic-Hajric S, Suljic E, Memic-Serdarevic A, Sulejmanpasic G, Mahmutbegovic N. Quality of life in multiple sclerosis patients: influence of gender, age and marital status. Mater Sociomed. 2022;34:19\u201324.","journal-title":"Mater Sociomed"},{"key":"603_CR47","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fneur.2017.00577","volume":"8","author":"AM Weideman","year":"2017","unstructured":"Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol. 2017;8:577.","journal-title":"Front Neurol"},{"key":"603_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2023.107612","volume":"225","author":"M Salavisa","year":"2023","unstructured":"Salavisa M, Serrazina F, Ladeira AF, Correia AS. Discontinuation of disease-modifying therapy in MS patients over 60\u00a0years old and its impact on relapse rate and disease progression. Clin Neurol Neurosurg. 2023;225: 107612.","journal-title":"Clin Neurol Neurosurg"},{"key":"603_CR49","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/ene.12690","volume":"22","author":"A Signori","year":"2015","unstructured":"Signori A, Schiavetti I, Gallo F, Sormani MP. Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials. Eur J Neurol. 2015;22:960\u20136.","journal-title":"Eur J Neurol"},{"key":"603_CR50","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1007\/s00415-019-09248-6","volume":"266","author":"B Turner","year":"2019","unstructured":"Turner B, Cree BAC, Kappos L, et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol. 2019;266:1182\u201393.","journal-title":"J Neurol"},{"key":"603_CR51","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/jamaneurol.2021.0764","volume":"78","author":"EMM Strijbis","year":"2021","unstructured":"Strijbis EMM, Kerbrat A, Corboy JR. Discontinuation of disease-modifying therapy in multiple sclerosis: should we stay or should we go? JAMA Neurol. 2021;78:787\u20138.","journal-title":"JAMA Neurol"},{"issue":"9856","key":"603_CR52","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase\u00a03 trial. Lancet. 2012;380(9856):1819\u201328.","journal-title":"Lancet"},{"issue":"9856","key":"603_CR53","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase\u00a03 trial. Lancet. 2012;380(9856):1829\u201339.","journal-title":"Lancet"},{"key":"603_CR54","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","volume":"359","author":"AJ Coles","year":"2008","unstructured":"CAMMS223 Trial Investigators, Coles AJ, Compston DA, et al. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786\u2013801.","journal-title":"N Engl J Med"},{"key":"603_CR55","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416\u201326.","journal-title":"N Engl J Med"},{"key":"603_CR56","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1177\/13524585231161494","volume":"29","author":"G Giovannoni","year":"2023","unstructured":"Giovannoni G, Boyko A, Correale J, et al. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY Extension cohort of CLASSIC-MS: an ambispective study. Mult Scler. 2023;29:719\u201330.","journal-title":"Mult Scler"},{"key":"603_CR57","doi-asserted-by":"publisher","first-page":"P262","DOI":"10.1016\/j.msard.2018.10.097","volume":"26","author":"G Giovanonni","year":"2018","unstructured":"Giovanonni G, Rammohan K, Cook S, et al. Cladribine tablets 35\u00a0mg\/kg is efficacious in patients aged above and below 45\u00a0years with relapsing multiple sclerosis in the clarity study. Mult Scler Relat Disord. 2018;26:P262.","journal-title":"Mult Scler Relat Disord"},{"key":"603_CR58","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/1352458520921087","volume":"27","author":"N Lizak","year":"2021","unstructured":"Lizak N, Hodgkinson S, Butler E, et al. Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase registry substudy. Mult Scler. 2021;27:465\u201374.","journal-title":"Mult Scler"},{"key":"603_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103490","volume":"58","author":"G Disanto","year":"2022","unstructured":"Disanto G, Moccia M, Sacco R, et al. Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50\u00a0years. Mult Scler Relat Disord. 2022;58:103490.","journal-title":"Mult Scler Relat Disord"},{"key":"603_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102717","volume":"49","author":"AD Bass","year":"2021","unstructured":"Bass AD, Arroyo R, Boster AL, et al. Alemtuzumab outcomes by age: post hoc analysis from the randomized CARE-MS studies over 8\u00a0years. Mult Scler Relat Disord. 2021;49:102717.","journal-title":"Mult Scler Relat Disord"},{"key":"603_CR61","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","volume":"29","author":"G Comi","year":"2019","unstructured":"Comi G, Cook S, Giovannoni G, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:168\u201374.","journal-title":"Mult Scler Relat Disord"},{"key":"603_CR62","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s40120-023-00496-3","volume":"12","author":"P Clavelou","year":"2023","unstructured":"Clavelou P, Castelnovo G, Pourcher V, et al. Expert narrative review of the safety of cladribine tablets for the management of relapsing multiple sclerosis. Neurol Ther. 2023;12:1457\u201376.","journal-title":"Neurol Ther"},{"key":"603_CR63","doi-asserted-by":"publisher","unstructured":"Giovannoni G, Leist T, Jack D, Galazka A. Updated post-approval safety of cladribine tablets in the treatment of multiple sclerosis, with particular reference to liver safety. Abstract 341 at the 2022 meeting of ECTRIMS, October 26\u201328 2022. https:\/\/doi.org\/10.1177\/13524585221123687.","DOI":"10.1177\/13524585221123687"},{"key":"603_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.763433","volume":"12","author":"G Giovannoni","year":"2021","unstructured":"Giovannoni G, Coyle PK, Vermersch P, et al. Integrated lymphopenia analysis in younger and older patients with multiple sclerosis treated with cladribine tablets. Front Immunol. 2021;12:763433.","journal-title":"Front Immunol"},{"key":"603_CR65","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24:1594\u2013604.","journal-title":"Mult Scler"},{"key":"603_CR66","first-page":"205521731773280","volume":"3","author":"MS Freedman","year":"2017","unstructured":"Freedman MS, Leist TP, Comi G, et al. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: results from the ORACLE-MS study. Mult Scler J Exp Transl Clin. 2017;3:2055217317732802.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"603_CR67","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","volume":"29","author":"S Cook","year":"2019","unstructured":"Cook S, Leist T, Comi G, et al. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis. Mult Scler Relat Disord. 2019;29:157\u201367.","journal-title":"Mult Scler Relat Disord"},{"key":"603_CR68","doi-asserted-by":"crossref","unstructured":"Herpes zoster (shingles) vaccination update. Aust Prescr. 2023;46:91.","DOI":"10.18773\/austprescr.2023.027"},{"key":"603_CR69","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s40120-023-00497-2","volume":"12","author":"J Inshasi","year":"2023","unstructured":"Inshasi J, Farouk S, Shatila A, et al. Multicentre observational study of treatment satisfaction with cladribine tablets in the management of relapsing multiple sclerosis in the Arabian Gulf: the CLUE study. Neurol Ther. 2023;12:1309\u201318.","journal-title":"Neurol Ther"},{"key":"603_CR70","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1590\/0004-282X20130081","volume":"71","author":"GS Olival","year":"2013","unstructured":"Olival GS, Cavenaghi VB, Serafim V, Thomaz RB, Tilbery CP. Medication withdrawal may be an option for a select group of patients in relapsing-remitting multiple sclerosis. Arq Neuropsiquiatr. 2013;71:516\u201320.","journal-title":"Arq Neuropsiquiatr"},{"key":"603_CR71","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","volume":"22","author":"JR Corboy","year":"2023","unstructured":"Corboy JR, Fox RJ, Kister I, et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase\u00a04, non-inferiority trial. Lancet Neurol. 2023;22:568\u201377.","journal-title":"Lancet Neurol"},{"issue":"3S","key":"603_CR72","first-page":"356","volume":"29","author":"J Corboy","year":"2023","unstructured":"Corboy J, Engebretson E, Cutter G, et al. DISCOntinuation of disease-modifying therapies in multiple sclerosis (DISCOMS): primary results of the extension trial. Mult Scler J. 2023;29(3S):356.","journal-title":"Mult Scler J"},{"issue":"3S","key":"603_CR73","first-page":"76","volume":"29","author":"E Coerver","year":"2023","unstructured":"Coerver E, Fung WH, De Beukelaar J, et al. Discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS): an early terminated multicenter randomized controlled trial. Mult Scler J. 2023;29(3S):76.","journal-title":"Mult Scler J"},{"key":"603_CR74","doi-asserted-by":"publisher","unstructured":"Jouvenot G, Courbon G, Lefort M, et al. Effects of high-efficacy therapy discontinuation vs continuation in patients with non-active multiple sclerosis aged over 50. JAMA Neurol 2024. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0395","DOI":"10.1001\/jamaneurol.2024.0395"},{"key":"603_CR75","doi-asserted-by":"publisher","first-page":"e1926","DOI":"10.1212\/WNL.0000000000201029","volume":"99","author":"I Roos","year":"2022","unstructured":"Roos I, Malpas C, Leray E, et al. Disease reactivation after cessation of disease-modifying therapy in patients with relapsing-remitting multiple sclerosis. Neurology. 2022;99:e1926\u201344.","journal-title":"Neurology"},{"key":"603_CR76","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40120-022-00430-z","volume":"12","author":"J De S\u00e8ze","year":"2023","unstructured":"De S\u00e8ze J, Suchet L, Mekies C, et al. The place of immune reconstitution therapy in the management of relapsing multiple sclerosis in France: an expert consensus. Neurol Ther. 2023;12:351\u201369.","journal-title":"Neurol Ther"},{"key":"603_CR77","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40120-019-0129-0","volume":"8","author":"R Alroughani","year":"2019","unstructured":"Alroughani R, Inshasi JS, Deleu D, et al. An overview of high-efficacy drugs for multiple sclerosis: gulf region expert opinion. Neurol Ther. 2019;8:13\u201323.","journal-title":"Neurol Ther"},{"key":"603_CR78","unstructured":"Multiple Sclerosis Trust. NEDA (no evidence of disease activity). https:\/\/mstrust.org.uk\/a-z\/neda-no-evidence-disease-activity. Accessed Nov 2023."},{"key":"603_CR79","first-page":"205521732311825","volume":"9","author":"H Kelly","year":"2023","unstructured":"Kelly H, Vishnevetsky A, Chibnik LB, Levy M. Hypogammaglobulinemia secondary to B\u00a0cell depleting therapies in neuroimmunology: comparing management strategies. Mult Scler J Exp Transl Clin. 2023;9:20552173231182536.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"3S","key":"603_CR80","first-page":"852","volume":"28","author":"R Sacco","year":"2022","unstructured":"Sacco R, Disanto G, Pravat\u00e0 E, Gobbi C, Zecca C. Safety and efficacy of cladribine therapy following a treatment with anti-CD20 compounds in relapsing multiple sclerosis patients: a pilot study. Mult Scler J. 2022;28(3S):852.","journal-title":"Mult Scler J"},{"key":"603_CR81","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/ageing\/afz021","volume":"48","author":"G Ellis","year":"2019","unstructured":"Ellis G, Sevdalis N. Understanding and improving multidisciplinary team working in geriatric medicine. Age Ageing. 2019;48:498\u2013505.","journal-title":"Age Ageing"},{"issue":"3S","key":"603_CR82","first-page":"633","volume":"29","author":"MC Ysrraelit","year":"2023","unstructured":"Ysrraelit MC, Piedrabuena MA, Fiol M, et al. Selection of high efficacy disease modifying therapies in multiple sclerosis patients older than 50\u00a0years. Mult Scler J. 2023;29(3S):633 (Abstract).","journal-title":"Mult Scler J"},{"key":"603_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104951","volume":"79","author":"W Brownlee","year":"2023","unstructured":"Brownlee W, Amin A, Ashton L, Herbert A. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: the CLARENCE study. Mult Scler Relat Disord. 2023;79:104951.","journal-title":"Mult Scler Relat Disord"},{"key":"603_CR84","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1007\/s12325-020-01349-3","volume":"37","author":"F Lenz","year":"2020","unstructured":"Lenz F, Harms L. The impact of patient support programs on adherence to disease-modifying therapies of patients with relapsing-remitting multiple sclerosis in Germany: a non-interventional, prospective study. Adv Ther. 2020;37:2999\u20133009.","journal-title":"Adv Ther"},{"key":"603_CR85","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043930","volume":"11","author":"C Evans","year":"2021","unstructured":"Evans C, Marrie RA, Yao S, et al. Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study. BMJ Open. 2021;11:e043930.","journal-title":"BMJ Open"},{"key":"603_CR86","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40120-022-00339-7","volume":"11","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Mathews J. Cladribine tablets for relapsing-remitting multiple sclerosis: a clinician\u2019s review. Neurol Ther. 2022;11:571\u201395.","journal-title":"Neurol Ther"},{"key":"603_CR87","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s40120-022-00394-0","volume":"11","author":"V Meca-Lallana","year":"2022","unstructured":"Meca-Lallana V, Garc\u00eda Dom\u00ednguez JM, L\u00f3pez Ruiz R, et al. Expert-agreed practical recommendations on the use of cladribine. Neurol Ther. 2022;11:1475\u201388.","journal-title":"Neurol Ther"},{"key":"603_CR88","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s40120-021-00243-6","volume":"10","author":"JS Inshasi","year":"2021","unstructured":"Inshasi JS, Alfahad S, Alsaadi T, et al. Position of cladribine tablets in the management of relapsing-remitting multiple sclerosis: an expert narrative review from the United Arab Emirates. Neurol Ther. 2021;10:435\u201354.","journal-title":"Neurol Ther"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00603-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00603-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00603-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T07:33:23Z","timestamp":1716968003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00603-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["603"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00603-y","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"assertion":[{"value":"13 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jerome de Seze has received fees for consultancy, advisory board and clinical trials from UCB, Novartis, Biogen, Merck, Teva, Genzyme\/ Sanofi, Roche, Alexion, BMS\/Celegene, Janssen, Horizon Therapeutics. Dominique Dive has received fees for consultancy, advisory board and clinical trials from Novartis, Biogen, Merck, Teva, Genzyme\/ Sanofi, Roche, Alexion, BMS\/Celegene, Janssen. Xavier Ayrignac has received consulting and lecturing fees, travel grants, and unconditional research support from Alexion, Biogen, Genzyme, Janssen, Novartis, Merck Serono, Roche, and Teva Pharma. Giovanni Castelnovo received fees for consulting and speaking from Biogen, Abbvie, Merck, Novartis, Roche, Sanofi Genzyme, Merz, Celgene BMS. Marianne Payet and Amel Rayah are employees of Merck Sant\u00e9 S.A.S., Lyon, France, an affiliate of Merck KGaA. Ente Ospedaliero Cantonale (employer) received compensation for Chiara Zecca\u2019s speaking activities, consulting fees, or grants from Abbvie, Almirall, Biogen Idec, Bristol Meyer Squibb, Lundbeck, Merck, Novartis, Sandoz, Sanofi, Teva Pharma, Roche. CZ is recipient of a grant for senior researchers provided by AFRI (Area Formazione accademica, Ricerca e Innovazione), EOC. Patrick Vermersch received honoraria for contributions to meetings from Biogen, Sanofi-Genzyme, Novartis, Teva, Merck, Roche, Imcyse, AB Science, Ad scientiam and BMS-Celgene, and research support from Novartis, Sanofi-Genzyme and Merck. Ente Ospedaliero Cantonale (employer) received compensation for Claudio Gobbi\u2019s speaking activities, consulting fees, or grants from Almirall, Biogen Idec, Bristol Meyer Squibb, Merck, Novartis, Sandoz, Sanofi, Teva Pharma, Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This narrative review is based on previously conducted studies and the clinical expertise of the authors in treating patients with RMS. No new clinical studies were performed by the authors. No patient-specific efficacy or safety data were reported. Therefore, institutional review board (IRB)\/ethics approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}